Abstract
When used at a high dose, many anticancer drugs produce undesirable side effects including hepatotoxicity. Transdermal delivery bypasses first-pass metabolism, allowing the use of a lower dose of drug while decreasing systemic toxicity. In this review, we summarize various advanced technologies for improving anticancer drug delivery via the skin. This technology is discussed in the context of three anticancer drugs, 5-fluorouracil (5-FU), methotrexate (MTX) and 5-aminolevulinic acid (5-ALA). The use of a erbium:YAG (Er:YAG) laser for transdermal delivery of anticancer drugs is specifically highlighted in this review.
| Original language | English |
|---|---|
| Pages (from-to) | 592-597 |
| Number of pages | 6 |
| Journal | Current Drug Metabolism |
| Volume | 9 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Anticancer drugs
- Laser
- Toxicity
- Transdermal delivery
Fingerprint
Dive into the research topics of 'Decreasing systemic toxicity via transdermal delivery of anticancer drugs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver